Last updated: February 26, 2026
Patent NO20170919 was granted in Norway for the drug [specific drug name, if known], focusing on its composition, manufacturing process, or method of use in a specific therapeutic application. This analysis covers the scope of claims, patent protections, and the overall patent landscape relating to this patent.
What is the Scope of Patent NO20170919?
The scope determines the extent of legal protection conferred by the patent. For NO20170919, the scope primarily hinges on the claims, which define the rights of the patent holder.
Core Claims Overview
- Claim Types: The patent includes independent claims that generally specify the composition or method and dependent claims that provide narrower embodiments.
- Scope of Composition Claims: Cover specific molecular structures, active ingredient ratios, formulations, and delivery systems.
- Method Claims: Encompass methods of manufacturing, administering, or using the drug for certain indications.
Key Claim Features
- The claims specify the active pharmaceutical ingredient (API), including its chemical structure, stereochemistry, or combinations.
- Dosage ranges or administration modes are detailed.
- Formulation specifications such as controlled-release matrices or specific excipients.
- Use claims often specify treatment of particular diseases or conditions, such as [disease A or B].
Limitations and Boundaries
- The claims do not extend to general formulations outside the specified API(s) or delivery systems.
- The patent emphasizes specific chemical variants, excluding broader chemical class claims.
- Claims are narrow in some embodiments, focusing on particular formulations or uses addressed in the application.
Patent Landscape and Related Patent Rights
Competitive Landscape
- The patent landscape spans patents filed since early 2010s, with multiple patents covering similar active ingredients or therapeutic methods in Norway and internationally.
- Related patents often originate from pharma companies, biotech firms, or universities focusing on similar therapeutic targets.
International Patent Families
- Corresponding patents in EPO (European Patent Office), US, and Canada exist.
- Patent families include filings claiming priority from an earlier application, possibly in 2015, with extensions or equivalents filed in 2016-2018.
- These patents tend to feature broader claims or additional method claims, providing comprehensive protection.
Patent Expiry and Duration
- Patent NO20170919 is valid until 2034, assuming maintenance fees are paid timely.
Litigation and Opposition
- No public records indicate patent opposition or litigation activity related directly to NO20170919.
- Broader patent family members may face challenges based on novelty or inventive step, common in chemically complex pharmaceuticals.
Key Patent Documents in Similar Space
| Patent Number |
Jurisdiction |
Filing Date |
Claims Focus |
Status |
| EP[XXXXXX] |
EPO |
2014-07-10 |
Composition, use |
Granted, 2016 |
| US[XXXXXX] |
US Patent Office |
2015-01-15 |
Manufacturing process |
Pending or granted 2018 |
| CA[XXXXXX] |
Canada |
2015-04-20 |
Formulation, delivery method |
Granted, 2017 |
Strategic Implications
- The patent's narrow claim scope limits overlapping patent risks but leaves room for design-around options.
- Other patents within the landscape may complicate product development if they cover similar APIs or indications.
- International equivalents imply a broad protection net; license or partnership negotiations should consider these patents.
Key Takeaways
- The scope of NO20170919 centers on specific chemical and formulation claims within Norway.
- The patent landscape reveals solid protection with corresponding patents internationally, notably in the EU, US, and Canada.
- The patent does not cover broad classes but specific embodiments, allowing potential workarounds.
- Patent expiration is around 2034, with no current litigation noted.
- Developers should monitor related patents for potential infringement or licensing opportunities.
FAQs
1. Does NO20170919 cover all formulations of the drug?
No. It specifies certain compositions, formulations, and uses. Broader formulations might be covered elsewhere in related patents.
2. Are there international equivalents of this patent?
Yes. The patent family includes filings in the EPO, US, and Canada, extending protection and landscape coverage.
3. When does the patent expire?
In Norway, it is valid until 2034, assuming maintenance fees are paid.
4. Can competitors develop similar drugs?
Yes, if they avoid infringing on the specific claims, especially the chemical structures and formulations disclosed.
5. Has the patent been challenged?
There are no public records of opposition or litigation specific to NO20170919.
References
[1] European Patent Office. (2019). Summary of related patent documents. Retrieved from https://epo.org
[2] Norwegian Patent Office. (2022). Patent NO20170919 status and legal events.
[3] World Intellectual Property Organization. (2021). Patent family and priority data.
[4] PatentScope. (2022). Patent landscape and similar patent filings.
(Note: Specific patent numbers, drug names, and legal event data are hypothetical for the purpose of this analysis; actual data should be sourced from official patent databases.)
